You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 5, May 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on ISI (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •General Rhinology
 •Paranasal Sinus Disease
 •Pulmonary Diseases
 •Pulmonary Diseases, Other
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Genetics
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Nasally Inhaled Dornase Alfa in the Postoperative Management of Chronic Sinusitis Due to Cystic Fibrosis

Eileen M. Raynor, MD; Allen Butler, MD; Margaret Guill, MD; John P. Bent III, MD

Arch Otolaryngol Head Neck Surg. 2000;126:581-583.

Objective  To determine the benefit of nasally inhaled dornase alfa in cystic fibrosis (CF) sinusitis.

Design  Retrospective chart review comparing postsurgical course, radiographic studies, and pulmonary function test results in patients who were treated with nasally inhaled dornase alfa with those in patients who were not treated with dornase alfa.

Patients  Twenty consecutive patients with CF who underwent functional endoscopic sinus surgery from 1993 to 1997 were included in the study. Treatment with nasally inhaled dornase alfa was initiated in 5 of the 20 patients after they underwent functional endoscopic sinus surgery.

Setting  Tertiary care academic center.

Results  The dornase alfa–treated patients had less mucosal edema and no polyps at serial endoscopy over 3 years compared with the non–dornase alfa–treated patients. The patients who received nasally inhaled dornase alfa also underwent fewer revision functional endoscopic sinus surgical procedures (1.6 vs 3.2), even though there was essentially no change in pulmonary function test results in these patients.

Conclusions  Sinusitis continues to be a major cause of morbidity in patients with CF. Symptomatic patients frequently require multiple drug regimens, including long-term systemic antibiotic therapy, topical and systemic steroid therapy, and antibiotic nasal irrigations. This preliminary study indicates the potential impact of nasally inhaled dornase alfa in controlling postoperative symptoms in CF sinusitis.


From the Department of Otolaryngology, University of Florida–Health Science Center Jacksonville (Dr Raynor); the Department of Surgery, Division of Otolaryngology (Dr Butler), and the Division of Pulmonary Medicine (Dr Guill), Medical College of Georgia, Augusta; and New York Ear Associates, Lenox Hill, NY (Dr Bent).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dornase Alfa as Postoperative Therapy in Cystic Fibrosis Sinonasal Disease
Cimmino et al.
Arch Otolaryngol Head Neck Surg 2005;131:1097-1101.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.